Background {#Sec1}
==========

Pierson syndrome (PS) is a rare autosomal recessive disorder, characterized by congenital nephrotic syndrome and microcoria \[[@CR1]\]. These phenotypes are caused by the mutations of *LAMB2*, which encodes laminin β2 \[[@CR2]\]. Among various isoforms, Laminin-521 is known to be the most common isoform containing the β2 subunit \[[@CR3]\]. In accordance with the expression of *LAMB2* at the neuromuscular junctions, patients with PS show severe muscular hypotonia and developmental delay \[[@CR2]\].

The majority of patients with PS die of renal failure within the first year of life. Despite this vital symptom, recent evidence has shown that the implementation of renal replazcement therapy in infancy is effective for extending life span \[[@CR4], [@CR5]\]. On the other hand, the full clinical spectrum of the long-term survivors and the time course of neuromuscular complications remain elusive. In this report, we present the case of a patient with PS carrying a compound heterozygous mutation in *LAMB2*. The patient showed progressive gastrointestinal as well as dysautomomic features as novel complications of PS.

Case presentation {#Sec2}
=================

The patient, a 12-month-old boy was the third child of non-consanguineous, healthy parents. He had healthy sisters of 5 and 4 years of age. The patient was born via vaginal delivery without asphyxia at 35 weeks of gestational age. The patient's birth weight, length and head circumference were 2342 g (0.0 SD), 45.2 cm (0.0 SD) and 33.4 cm (1.2 SD), respectively. The placental weight was 850 g. Oliguria continued from birth, and the serum creatinine level was elevated to 2.63 mg/dl on the 5th day of age. Congenital nephrotic syndrome was suspected based on the detection of hypoalbuminemia (2.1 g/dl) and proteinuria (3+ on dipstick).

He was transferred to our hospital at 6 days of age. On admission, his consciousness was alert and his vital signs were stable: respiratory rate 37/min, heart rate 149/min, and blood pressure 84/54 mmHg. Bilateral microcoria and nystagmus were evident. The body posture and voluntary movements were normal. The muscular tone appeared normal. Deep tendon reflex was brisk. Laboratory tests confirmed that the urine protein/creatinine ratio was increased to 95.1 mg/mg Cre. Renal ultrasonography showed hyperechoic signals in both kidneys with unclear cortico-medullary structures. Continuous hemodiafiltration was introduced at 7 days of age, which was then replaced by peritoneal dialysis from 12 days of age. He became anuric during the course and continued peritoneal dialysis afterwards. With these renal replacement therapies, he survived the first 12 months of life.

Intestinal malrotation was diagnosed after the patient began experiencing recurrent vomiting started at 6 months of age (Fig. [1](#Fig1){ref-type="fig"}a). The volvulus was successfully relieved by surgery. However, the vomiting signs persisted beyond the surgical repair due to the presence of another digestive dysfunction, gastroesophageal reflux (Fig. [1](#Fig1){ref-type="fig"}b). Although duodenal tube feeding was introduced, only limited amounts of nutrition could be provided, which proved insufficient to achieve weight gain during the 12-month follow-up period. Thus, tulobuterol (0.2 mg/day) was given orally from 12 months. The patient's vomiting disappeared immediately after tulobuterol treatment, and his weight continued to increase until the time of writing this report. In the last month, it reached 5300 g (+ 300 g). Patients on peritoneal dialysis are also known to develop thyroid dysfunctions \[[@CR6]\]. We verified that serum thyroid stimulating hormone (2.70 μIU/mL) and free thyroxine (1.48 ng/dL) levels remained unaltered. We thus did not interpret hyper- or hypothyroidism as a primary cause of his gastrointestinal problems. Fig. 1Gastrointestinal phenotypes associated with Pierson syndrome. **a** An upper gastrointestinal contrast study depicting the intestinal malrotation. Arrows indicate the "corkscrew sign" of the proximal jejunum. **b** A radiographic contrast image depicting the gatroesophageal reflux (arrow head)

Serial neurological assessments demonstrated that he had started gazing at and pursuing the objects from 2 months of age. However, generalized muscle weakness and hypotonia became prominent from 3 months of age. Presently at 12 months of age, his developmental quotient score is considered to be less than 20 (equivalent to the score of an infant of 2--3 months of age). He has been unable to control his neck, roll over, or sit unaided. Electrocardiography showed normal sinus rhythm and a normal axis with a corrected QT interval of 356 msec. The coefficient of variation in electrocardiographic R-R intervals (13.5%) remained within the normal range. Echocardiography demonstrated the balance of the 4 chambers and a normal left-heart function with an ejection fraction of 82.9%.

The clinical features of congenital nephrotic syndrome with microcoria prompted us to conduct the genetic testing for the diagnosis of PS. Whole-exome sequencing followed by the Sanger method showed that the patient harbored a compound heterozygous mutations in exon 14 (NM_002292.3:c.1648C \> T:p.Arg550X) and exon 27 (NM_002292.3:c.4519C \> T:p.Glu1507X) in the *LAMB2* gene (Fig. [2](#Fig2){ref-type="fig"}a). An inheritance analysis demonstrated that his father and mother carried the heterozygous mutations in exon 14 (NM_002292.3:c.4519C \> T:p.Glu1507X) and exon 27 (NM_002292.3:c.4519C \> T:p.Glu1507X), respectively. Thus, the patient was genetically diagnosed with PS. Fig. 2*LAMB2* mutations in this and previously reported cases of Pierson syndrome. **a** Sequencing chromatograms of the father, mother and the patient are shown. The 5′ to 3′ ends of the transcripts are indicated in combination with each diagram. Vertical arrows indicate the position of mutations; exon14 (c.1648C \> T:p.Arg550X) and exon 27 (c.4519C \> T:p.Glu1507X), and mutated codons are underlined. **b** Pathogenic mutations associated with the neuromuscular symptoms of PS are mapped to the functional domains of Laminin β2 protein. Red arrows: nonsense and frame-shift mutations; Black arrows: missense mutations and in-frame deletions. LAMNT, laminin N-terminal globular domain; EGFLAM, laminin EGF-like modules; CC, laminin coiled coil domain

We found 19 patients with PS, who have been reported to manifest severe neuro-muscular problems (Table [1](#Tab1){ref-type="table"}). All of these patients showed neurological signs of hypotonia or developmental delay, whereas their onset or time course was not described in detail. Eight patients survived 12 months after birth, and 7 of them received renal replacement therapy (dialysis or kidney transplantation) in early infancy. Among them, only one patient was reported to show gastrointestinal problems. No detailed information was available on the gastrointestinal features of the other long-term survivors. Table 1Summary of the patients with neuromuscular phenotypes of Pierson syndromeCaseAuthorYearMutationSexAge at the report (Status)Renal disease (Age at onset)Neurological findingOphthalmologyGastrointestinal symptomRenal replacementtherapy (Age)1Maselli RA2009p.C493SfsTer;p.Q1602RfsTer52F20 yearsProteinuriaESRD(Birth)Hypotonia, Motor delayMicrocoriaNAKidney transplant (15 months)2Wühl E2007p.Q1753fsTer7(homozygous)F19 months (Died)ProteinuriaESRD(Birth)Hypotonia, Motor delay,Cognitive deficits, MicrocephalyMicrocoria, Cataract, PHPVFeeding difficulty;gastrostomyPeritoneal dialysis (6 weeks)Kidney transplant(18 months)3Zenker M2004p.E1754GfsTer7(homozygous)NA19 months (Died)ProteinuriaESRD(\< 1 m)Hypotonia, Motor delayAbnormal lensNAPeritoneal dialysis4Wühl E2007p.C493fsTer3;p.E1301fsTer57F17 monthsProteinuriaESRD(Birth)Hypotonia, Motor delay, Cognitive deficits, MicrocephalyMicrocoria, Cataract, PHPVNAPeritoneal dialysis (7 weeks)5Matejas V2011p.R468fsTer37\[Intron 10 c.1405 + 1G \> A\] splicedonor site, paternal isodisomy ofCh3M17 months (Died of aspergillosis)ProteinuriaESRD(Birth)Hypotonia, Motor delay, Cognitive deficitsMicrocoria, Retinal detachmentNAPeritoneal dialysis (3 weeks)6Wühl E2007p.M415fsTer81;p.Q418TerF15 months (Died of sepsis)ProteinuriaESRD(Birth)Hypotonia, Motor delay, Cognitive deficits, MicrocephalyMicrocoria, Cataract, Retinal detachment,PHPVNAPeritoneal dialysis (3 weeks)7Bredrup C2008p.R246W;p.R575TerM15 monthsProteinuriaESRD(1w)Hypotonia, Motor delay, Cognitive deficits, MicrocephalyMicrocoria, Abnormal lensNANA8This report2018p.R550Ter;p.Q1507TerM12 monthsProteinuriaESRD(Birth)Hypotonia,Motor delayMicrocoriaIntestinalmalrotation, Severe gastroesophageal refluxHemodialysis (7 days) Peritoneal dialysis (12 days)9Matejas V2010p.L139P(homozygous)NA12 months (Died)Proteinuria(3 m)Hypotonia, Motor delay,Cognitive deficitsMicrocoria, Abnormal lensNANA10Zenker M2004p.R246W(homozygous)M8 months(Died of sepsis)Proteinuria(5 m)Hypotonia, abnormal movement ofright armMicrocoriaNANA11Zenker M2004p.R246W(homozygous)F8 months(Died of metaboliccause and infection)Proteinuria(5d)Hypotonia, Left hemiparesisMicrocoria, CataractNAPeritoneal dialysis (4 months)12Matejas V2010p.L139P(homozygous)NA5 months (Died)Proteinuria(\<1w)Hypotonia, Motor delayAbnormal lensNANA13Bredrup C2008p.Q868Ter;p.C1058TerM4.5 monthsProteinuriaESRD(2w)HypotoniaMicrocoriaNANA14Bredrup C2008p.V808WfsTer342(homozygous)M4 months (Died)ProteinuriaESRD(1w)Hypotonia, Motor delay, MicrocephalyMicrocoriaNANA15Bredrup C2008p.I149del;p.G1693VfsTer20M2 months (Died)ProteinuriaESRD(1w)HypotoniaMicrocoriaNANA16Matejas V2010p.E1636AfsTer22(homozygous)NA1.2 months (Died)ProteinuriaESRD(1w)Hypotonia,Motor delay,MicrocephalyMicrocoria, Abnormal lensNANA17Bredrup C2008p.L627AfsTer4;p.R1502GfsTer17M1 month (Died)ProteinuriaESRD(1w)HypotioniaMicrocoriaNA18Zenker M2005p.C374X;p.Y689XNA2 weeks (Died)ProteinuriaESRD(1w)HypotiniaMicrocoria, Abnormal lens,NANA19Zemrani B2016p.R964X(homozygous)M7 days (Died)ProteinuriaESRD(Birth)HypotoniaMicrocoriaNAPeritoneal dialysis (birth)*NA* data not available

Mutation maps of these 19 patients are graphically summarized in Fig. [2](#Fig2){ref-type="fig"}b. Notably, all truncating mutations were located outside the laminin N-terminal (LAMNT) globular domain and the missense or in-frame deletions were mapped to the LAMNT domain. This result indicated both the pathogenic impacts of the disrupted LAMB2 protein and the functional significance of the LAMNT domain.

Discussion and conclusions {#Sec3}
==========================

We reported the case of a patient with PS carrying truncating mutations in *LAMB2*. This report extended the phenotypic spectrum of PS by clarifying that gastrointestinal dysfunction emerged after the first few months of life. Earlier studies have demonstrated the clinical course of patients with PS, and clarified their pathological bases in both human subjects and animal models. In agreement with the clinical course of the present case, a previous report supports the notion that neuromuscular deficits may emerge and progress in early infancy \[[@CR5], [@CR7]--[@CR9]\]. In animal studies, the morphological analyses revealed that the number of presynaptic vesicles and the size of nerve termini at the neuro-muscular junctions (NMJ) did not differ between *Lamb2*-nulli mice and their littermates during the first few days of life \[[@CR10]\]. Notably, however, prominent differences emerged after postnatal day 7 \[[@CR11]\]. These findings suggest that laminin β2 is important for postnatal maturation of NMJ in both humans and mice during the first few weeks after birth. In this regard, the absence of neurological findings at birth does not imply that patients with PS will show mild symptoms in late infancy.

In addition to the detailed time course of the neurological findings, this report first disclosed that PS patients may develop intestinal malrotation and gastro-esophageal reflux. Notably, we found a report presenting the case of a patient with PS, who survived the neonatal period and underwent gastrostomy due to poor feeding \[[@CR12]\]. Experimental data also showed that laminin β2 is expressed in upper gastrointestinal tract \[[@CR13]\]. In some PS patients, neuromuscular symptoms showed initial improvement with the administration of oral ephedrine \[[@CR5]\]. The mode of action of β-stimulants is not fully understood; however, they increase the release of quanta of acetylcholine and reduce the acetylcholine receptor open time in vitro \[[@CR14], [@CR15]\]. Tulobuterol possibly acts at the autonomic nerve termini, which might have contributed to the amelioration of the gastrointestinal symptoms of this patient. These findings suggest that the gastrointestinal dysfunction is not a rare complication in patients with PS.

Intestinal malrotation represents a heterogeneous group of disorders, and the genetic backgrounds for this complex condition remain to be explored \[[@CR16]\]. Nonetheless, 4 main factors have been proposed to explain its underlying mechanisms: 1) abnormal left-right patterning, 2) an aberrant dorsal mesentery, 3) dysfunction of the intestine itself, or 4) dysfunction of other abdominal contents \[[@CR17]\]. Given the expression of *LAMB2* in the intestine, the third mechanism is likely to support the pathogenic link between PS and the intestinal malrotation in the present case. The correlations of the timeframe of the appearance of neurological signs and the intestinal malrotations will be explored more extensively in future studies with additional cases with PS.

This is the first report to delineate the time course of neurological signs and gastrointestinal involvements in a patient with PS, as well as the extended spectrum of the clinical phenotype.
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